Select a medication above to begin.
Norpace CR
disopyramide
Black Box Warnings .
Increased Mortality
excessive mortality or nonfatal cardiac arrest rate (7.7% encainide/flecainide vs. 3% placebo) in asymptomatic non-life-threatening ventricular arrhythmias w/ MI 6 days - 2 years prior; restrict use to life-threatening ventricular arrhythmias, no survival benefit in pts w/o life-threatening arrhythmias
Adult Dosing .
Dosage forms: ER CAP: 100 mg, 150 mg
ventricular arrhythmias
- [<50 kg]
- Dose: 200 mg ER PO q12h; Start: 200 mg IR PO x1; 100 mg IR PO q6-8h if cardiomyopathy or cardiac decompensation; Max: 1600 mg/day
- [>50 kg]
- Dose: 300 mg ER PO q12h; Start: 300 mg IR PO x1; 100 mg IR PO q6-8h if cardiomyopathy or cardiac decompensation; Max: 1600 mg/day
atrial fibrillation (off-label)
- [200-400 mg PO q12h]
- Max: 800 mg/day; Info: for maintenance rhythm control
renal dosing
- [see below]
- CrCl 41-59: 200 mg q12h; CrCl <41: avoid use
- HD/PD: not defined
hepatic dosing
- [adjust dose amount]
- hepatic impairment: 200 mg q12h
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.